The West Virginia Medicaid Drug utilization Review (DUR) Board meeting was called to order with the following in attendance:

**Members:**
Lester Labus, MD, Chair  
K.C. Lovin, PA-C, Vice Chair  
Michael Ballow, PharmD, (phone in)  
C.K. Babcock, PharmD  
Chris Booth, PharmD  
Scott Brown, RPh (phone in)  
Myra Chiang, MD  
Ernest Miller, DO  
Mary Nemeth-Pyles, MSN, RN, CS  
Christopher Terpening, PharmD, PhD  
John Vanin, MD

**Members Absent:**
Kate Forman, PharmD  
Michael Lonsinger, PharmD

**DHHR/BMS Staff:**
Vicki Cunningham, RPh, Director of Pharmacy Services  
Brian Thompson, MS, PharmD, DUR Coordinator  
Lori Moles, RPh, Staff Pharmacist  
Bill Hopkins, Pharmacy Operations Manager  
Doug Sorvig, Analyst

**Contract Staff:**
Angela Wowczuk, PharmD, Rational Drug Therapy Program (RDTPP)  
Alesha Heil, PharmD, SEMP  
Rob Stanton, PharmD, Marshall University  
Kim Broedel-Zaugg, RPh, PhD, Marshall University  
John Willis, Marshall University  
Eric Sears, RPh, DXC  
Brent Breeding, RPh, Change Healthcare  
Jeff Barken, MD, Change Healthcare (phone in)

I. INTRODUCTIONS  
a. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:10pm EDT. The DUR Board and attendees introduced themselves.

II. APPROVAL OF MINUTES FROM FEBRUARY 27, 2019 DUR BOARD MEETING  
a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.
III. **OLD BUSINESS**
   a. None

IV. **NEW BUSINESS**
   a. **Speakers**
      i. Kayleen Daly  
         J & J  
         Spravato
      ii. David Griffin  
         Takeda  
         Takhyzro
      iii. Ahmad Nesser  
         Amgen  
         Repatha
   b. **Updates from April 24, 2019 P & T Committee Meeting**
      i. Mr. Breeding presented the updates from the April 24, 2019 P & T meeting for board review. No changes were requested.
   c. **PDL Prior Authorization Criteria.** Attachment A
      i. Lovaza: Approved with amendments (removed requirement for niacin & fenofibrate)
      ii. CGM Devices (Dexcom G6, Freestyle Libre): Approved with amendments (added exception for patients under the age of 18 and removed A1C requirement).
      iii. Omnipod: Approved with amendments (added endocrinologist consult and removed A1C requirement)
      iv. PCSK9 Inhibitors: Approved as presented.
      v. Qbrexza: Approved as presented.
      vi. Spravato: Approved with amendments (changed prescriber requirement to REMS-certified, added psychiatrist-required diagnosis of TRD, and reduced required antidepressant trials to three).
      vii. HAE agents (Takhyzro): Approved as presented.
      viii. Xifaxan: Approved as presented (removed requirement for neomycin and metronidazole)

V. **REPORTS**
   a. **DXC Quarterly Report:** Mr. Sears presented an overview of the 2019 First Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
   b. **Rational Drug Therapy Program:** Dr. Wowczuk presented a review of the prior authorization program for the First Quarter of 2019. Attachment C
   c. **Marshall University:** Dr. Stanton reported on the progress of Retro DUR, the Pharmacy Lock-in program, and ideas for future interventions.

VI. **OTHER BUSINESS**
   a. Dr. Babcock requested that the P & T Committee consider adding Suboxone tablets as a Preferred agent.
   b. Dr. Thompson announced that Pharmacy Director Vicki Cunningham will be retiring in June.

VII. **NEXT MEETING AND ADJOURNMENT**
   a. A motion to adjourn the meeting was made, seconded, and passed.
   b. The meeting concluded at 6:20pm EDT.
   c. The next meeting will be September 25, 2019 from 4:00pm to 6:00pm and located at WVDHHR.